NASDAQ:ESLA Estrella Immunopharma Q4 2025 Earnings Results & Report $0.41 -0.01 (-1.80%) Closing price 04:00 PM EasternExtended Trading$0.34 -0.07 (-15.85%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Estrella Immunopharma beat analyst earnings expectations in its Q4 2025 results, released November 12, 2025. The company reported EPS of -$0.13 versus the -$0.1865 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateNovember 12, 2025TimeBefore Market Opens Estrella Immunopharma EPS ResultsActual EPS-$0.13Consensus EPS -$0.1865Beat/MissBeat by +$0.0565One Year Ago EPSN/AEPS Beat Rate4 of last 4 quartersEstrella Immunopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsEstrella Immunopharma's next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Estrella Immunopharma Q4 2025 Earnings FAQ Did Estrella Immunopharma beat earnings estimates for Q4 2025? Estrella Immunopharma (NASDAQ:ESLA) reported earnings of -$0.13 per share for Q4 2025, beating the consensus estimate of -$0.1865. The report was announced on Wednesday, November 12, 2025. When is Estrella Immunopharma's next earnings date? Estrella Immunopharma's next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Estrella Immunopharma on the company's earnings history page. Estrella Immunopharma Earnings HeadlinesEstrella Immunopharma (NASDAQ:ESLA) Shares Down 2.5% - Here's What HappenedOctober 7 at 2:03 AM | americanbankingnews.comEstrella’s EB103 Lymphoma Trial Advances, Keeping High-Risk Cell Therapy Hopes AliveOctober 1, 2026 | tipranks.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 9 at 1:00 AM | The Oxford Club (Ad)ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 TrialAugust 26, 2026 | finance.yahoo.comEstrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaAugust 11, 2026 | finance.yahoo.comEstrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaJuly 29, 2026 | finance.yahoo.comSee More Estrella Immunopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Estrella Immunopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Estrella Immunopharma and other key companies, straight to your email. Email Address About Estrella ImmunopharmaEstrella Immunopharma (NASDAQ:ESLA) is a clinical-stage biopharmaceutical company focused on developing T-cell-based immunotherapies for cancer and other serious diseases. The company’s research is centered on chimeric antigen receptor T-cell (CAR-T) therapies, which are designed to genetically modify a patient’s immune cells so they can recognize and attack targeted cells. Estrella’s lead program, EB-101, is an autologous CD19-directed CAR-T therapy being developed for the treatment of certain B-cell malignancies, including forms of leukemia and lymphoma. The company has also described additional development opportunities involving its CAR-T technology for other oncology and autoimmune indications. Its therapies remain investigational and are subject to clinical development and regulatory review. Estrella Immunopharma is headquartered in the United States and is listed on the Nasdaq under the symbol ESLA. The company’s public materials emphasize the development of cellular immunotherapies, although detailed information about commercial operations, geographic reach and leadership may change as its programs advance.View Estrella Immunopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
